
    
      To evaluate the safety and tolerance of single and multiple doses of IMMH-010 in patients
      with advanced solid tumors; To determine the maximum-tolerated dose (MTD) and recommended
      Phase II dose (RP2D) of IMMH-010; To evaluate the effects of food on the pharmacokinetic
      profiles after single dose of IMMH-010 in patients with advanced solid tumors.
    
  